The most common mTOR inhibitor is sirolimus (rapamycin), which was shown to prevent bleeding and anemia in preclinical mouse models of HHT by controlling VEGFR2 and mTOR overactivation (Robert et al., 2020). The gene discussed is KDR; the disease is anemia.